Business news
Belarus suggests setting up pharmaceutical clusters with Indian investors
Photo courtesy of the Council of the Republic
MINSK, 27 August (BelTA) – Sergei Rakhmanov, Chairman of the Standing Committee for Foreign Affairs and National Security of the Council of the Republic has met with India’s Biocon Limited delegation led by Alexander Zach, SVP, Head Market Access & Policy at Biocon Biologics Limited, to discuss cooperation prospects, including a possibility to set up joint pharmaceutical clusters, BelTA learned from the press service of the Council of the Republic.
Sergei Rakhmanov emphasized that promotion of the domestic pharmaceutical industry is one of Belarus’ priorities. In his view, the country has the necessary manufacturing and intellectual capacities for successful collaboration with Indian companies. “This pertains not only to export and import, but also to manufacturing, establishment of joint ventures and even clusters that would bring together representatives of the business community, science and education. We could work together on the markets of third countries,” he said.
The senator emphasized that Belarus amassed plenty of experience in IT and high technology. This expertise and knowledge can be used in the pharmaceutical industry, too. The representatives of Biocon Limited agreed with it. This kind of products are in great demand today. They cited a project to develop a mobile application for control and self-management of diabetes. “We are interested in such projects, therefore we will gladly discuss proposals of the Belarusian side, including those related to mobile health technology,” Alexander Zach said.
Another promising avenue of cooperation is transplantation. Belarusian specialists have already visited India to exchange best practices with fellow health professionals. This collaboration can grow in scale in the future.
The parties also discussed the transfer of Indian technology to produce cancer and diabetes medicines. They also considered the exchange of specialists.
Biocon Limited is India’s leading biopharmaceutical company that develops and produces biologics in chronic therapies such as diabetes, oncology and immunology for global markets. The company sells its products in more than 70 countries worldwide.
print version
make home page
add to bookmarks
